drugset
drugset / Trial / NCT04859426

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

NCT04859426 ↗

Phase 1 Completed 24 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild or moderate hepatic impairment (HI) compared to the matched control subjects with normal hepatic function.

Timeline

Start
2021-06-09
Primary completion
2022-05-14
Completion
2022-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject DBPR108 Small molecule 100 mg Oral

Indications

No indication recorded.